1. Yoshioka Y. (Symposium, invited) Long-term results of HDR monotherapy in the treatment of prostate cancer. ESTRO 37 (European Society for Radiotherapy and Oncology, 37th annual meeting), Barcelona, Spain, April 22, 2018
2. 吉岡靖生: シンポジウム：高線量率組織内照射(HDR)単独療法（シンポジウム：我が国にける高リスク・超高リスク前立腺がんの治療成績−局所治療が原病死リスク低減にどこまで貢献可能か？−）. 第106回日本泌尿器科学会総会. 2018. 京都.
3. 吉岡靖生: 前立腺癌の放射線治療（外部照射・小線源）. 第20回放射線腫瘍学夏季セミナー. 2018. 埼玉.
4. Taguchi S, Oguchi M, Yamaguchi M, Suzuki R, Ejima Y, Hasegawa M, Ishibashi N, Isobe K, Kasuya T, Sasai K, Shimoda E, Soejima T, Imai M. The Primary Tumor Invasion and Soluble Interleukin-2 Receptor as Prognostic Factors for Localized Nasal NK/T-cell Lymphoma: the Multi-institutional Retrospective Study u(NKEA project) in Japan. The 2018 Annual Meeting of the American Society for Radiation Oncology; Oct 2018. Texas, USA.
5. 田口千藏, 小口正彦, 山口素子, 鈴木律朗, 江島泰生, 長谷川正俊, 石橋直也, 磯部公一, 糟谷健夫, 笹井啓資, 下田絵美子, 副島俊典, 今井美智子. 限局期鼻腔NK/T細胞リンパ腫のPTIおよびsIL-2Rの予後予測に関する検討. 日本放射線腫瘍学会第31回学術大会. 2018. 京都.
6. 鈴木涼子ほか. Twice-daily TRT for small cell lung cancer dose not increase the risk of acute severe esophagitis. 日本放射線腫瘍学会第31回学術大会. 2018. 京都.
7. 鈴木涼子ほか. Re-irradiation of brain recurrence after whole brain irradiation for small cell lung cancer. 日本放射線腫瘍学会第31回学術大会. 2018. 京都.
8. 鈴木涼子ほか. Hematologic prognostic factors of brain failure in patients with small cell lung cancer. 日本放射線腫瘍学会第31回学術大会. 2018. 京都.
9. 佐々木理栄, 田口千藏, 桑原宏文, 吉岡靖生, 篠崎英司, 長嵜寿矢, 秋吉高志, 小西　毅, 福長洋介, 上野雅資, 小口正彦. 肛門管浸潤を有する下部進行直腸癌に対する術前化学放射線療法の予防領域に関する検討. 日本放射線腫瘍学会第31回学術大会. 2018. 京都.

1. Yoshioka Y. (Invited speaker) Current status and perspectives of high-dose-rate brachytherapy for prostate cancer. 16th National Meeting of Chinese Society of Therapeutic Radiation Oncology (CSTRO). Oct 2019. Shenzhen, China.
2. 吉岡靖生: ランチョンセミナー: 前立腺癌のホルモン療法 〜放射線科医の観点から〜. ガイドラインから見た放射線療法とホルモン療法の考え方. 第107回日本泌尿器科学会総会. 2019. 名古屋.
3. 吉岡靖生: イブニングセミナー: VISICOIL最前線2019: VISICOILとSpaceOARを用いた前立腺IGRT (TrueBeam). 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
4. 吉岡靖生: シンポジウム: 前立腺癌各種治療法の特徴: 高線量率組織内照射. 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
5. 吉岡靖生: ランチョンセミナー: よりよい前立腺がん治療を目指して　泌尿器科、放射線科の立場から　〜ハイドロゲルスペーサを用いた治療経験〜. 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
6. Taguchi S, Yoshioka Y, Mishima Y, Nishimura N, Yokoyama M, Takeuchi K, Terui Y, Oguchi M. Assessment of Late Toxicities of Liver and Kidney after Definitive Radiotherapy for Gastric MALT Lymphoma. The 2019 Annual Meeting of the American Society for Radiation Oncology; Sep. 2019. Chicago, USA.
7. 田口千藏, 吉岡靖生, 三嶋裕子, 西村倫子, 横山雅大, 竹内賢吾, 照井康仁, 小口正彦. 胃MALTリンパ腫放射線治療後の肝臓および腎臓の晩期毒性に関する検討. 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
8. 鈴木涼子、吉田匡宏、小口正彦、吉岡靖生、徳増 健二、大迫智、大野真司、上野貴之、宮城由美 Efficacy of radiation for focally tumor-exposed margin after breast conserving surgery: an update. 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
9. 篠村一磨、鈴木涼子、小塚拓洋、吉岡靖生、小口正彦　椎体の転移性骨腫瘍に対するIMRTによる再照射の有用性の検討　日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
10. 佐々木理栄, 田口千藏, 桑原宏文, 吉岡靖生, 篠崎英司, 長嵜寿矢, 秋吉高志, 小西　毅, 福長洋介, 上野雅資, 小口正彦. 肛門管浸潤を有する下部進行直腸癌に対する術前化学放射線療法の予防領域に関する検討. 第57回日本癌治療学会学術集会. 2019. 福岡.

1. 吉岡靖生, 伊藤誠,高瀬裕樹, 鈴木淳司, 奥田隆仁, 小口正彦. シンポジウム：体幹部定位放射線治療のトピックス：前立腺癌に対する体幹部定位放射線治療. 第29回日本定位放射線治療学会. 2020. 東京→WEB開催.
2. Taguchi S, Sasaki R, Yoshioka Y, Mishima Y, Nishimura N, Yokoyama M, Terui Y, Takeuchi K, Tsuji H, Oguchi M. Prognosis and Patterns of Relapse after Radiotherapy for Localized Ocular Adnexal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue (MALT Lymphoma). The 2020 Annual Meeting of the American Society for Radiation Oncology; Oct. 2020. Virtual Meeting.
3. 佐々木理栄, 田口千藏, 吉岡靖生, 中島大, 伊藤裕志, 三嶋裕子, 西村倫子, 横山雅大, 照井康仁, 竹内賢吾, 辻　英貴, 小口正彦. 限局期眼付属器MALTリンパ腫に対する根治的放射線治療後の白内障に関する検討. 日本放射線腫瘍学会第33回学術大会. 2020.10. WEB開催.

1. 吉岡靖生. (Webinar)：Radical Treatment Forum　根治療法をどう考える？ 〜患者背景に応じたモダリティ選択〜 第3回：高リスク前立腺癌における根治治療を見直す. 2021.3.東京.
2. 吉岡靖生. 特別講演: 前立腺癌の放射線治療の最前線とハイドロゲルスペーサー. 第3回浦安Urology & Radiology Meeting. 2021.9.浦安
3. 田口千藏：消化管癌の放射線治療．第32回がん放射線治療看護セミナー．2021.3. オンライン開催
4. 田口千藏．特別講演.：がん研有明病院における放射線治療の経験−悪性リンパ腫，直腸癌−．第12回中・四国放射線治療夏季セミナー．2021.7. オンライン開催
5. 田口千藏：悪性リンパ腫の放射線治療．第22回放射線腫瘍学夏季セミナー．2021.8. ハイブリッド開催
6. 佐々木理栄, 田口千藏, 篠崎英司, 日吉幸晴, 向井俊貴, 山口智弘, 長嵜寿矢, 秋吉高志, 福長洋介，小口正彦，吉岡靖生. ：肛門管腺癌に対する術前照射の予防領域に関する検討. 日本放射線腫瘍学会第34回学術大会. 2021.11. オンライン開催
7. Tran KH, Tsang RW, Suh CO, Yoon HI, Taguchi S, Oguchi M, Gunter JR, Dabaja B, Wright CM, Plastaras JP, Elsayad K, Ng AK, Binkley MS, Brady JL, Wang X, Levis M, Harris M, Bressel M, MacManus MP, Wirth A. An International, Multi-Centre Study of Radiotherapy for Bilateral Indolent Orbital Lymphomas (IOAL). The 2021 Annual Meeting of the American Society for Radiation Oncology; Oct. 2021. Chicago, USA

1. 吉岡靖生, 田口千藏, 原田亜里咲：RTは5回をめざす？：直腸術前、乳癌術後、前立腺の5回照射の文献的考察.第20回九州放射線治療システム研究会.; 2021年度 2022.02, Web開催.  [特別講演]
2. 吉岡靖生：超寡分割治療に向けたCKの狙い. サイバーナイフ研究会第15回学術研究会; 2021年度 2022.03, Web開催.  [シンポジウム]
3. 吉岡靖生：前立腺癌に対する高線量率組織内照射(HDR)と定位照射(SBRT）.日本放射線腫瘍学会小線源治療部会第24回学術大会; 2022年度 2022.05, 東京.SY2-3 [シンポジウム]
4. 吉岡靖生：ここまできた！前立腺がん放射線治療：最新の放射線治療.市民公開講座：前立腺がんに対する外照射放射線治療; 2022年度 2022.06, Web開催.  [講演]
5. 利安隆史：化学放射線療法1.第46回日本頭頸部癌学会; 2022年度 2022.06, 奈良市.  [口演;司会]
6. 吉岡靖生：インターベンション施行医が知っておくべき放射線治療の進歩.第30回日本心血管インターベンション治療学会学術集会; 2022年度 2022.07, 横浜市+Web開催.  [合同企画]
7. Yoshioka Y. (Webinar); Japanese experience of CyberKnife-SBRT for prostate cancer: Early clinical outcomes and dosimetrist comparison with high-dose-rate brachytherapy or gantry-based linear accelerator-SBRT. Accuray Exchange Webinar. September 22, 2022 (WEB)
8. Yoshioka Y. (Invited speaker); Prostate cancer ultrahypofractionation using high-dose-rate brachytherapy without perirectal spacer or stereotactic body radiotherapy with perirectal spacer. China Anti-Cancer Association Brachytherapy Academic Meeting, Nanjing, China, September 24, 2022 (recorded video slides)
9. 吉岡靖生：MR in RT for high accuracy radiation therapy.日本放射線腫瘍学会第35回学術大会; 2022年度 2022.11, 広島. [ランチョンセミナー;司会]
10. 吉岡靖生：前立腺癌に対する低線量率および高線量率小線源治療.日本放射線腫瘍学会第35回学術大会; 2022年度 2022.11, 広島. [シンポジウム]
11. 利安隆史：下咽頭表在癌に対する放射線単独療法の成績.日本放射線腫瘍学会第35回学術大会; 2022年度 2022.11, 広島. [一般口演]
12. 田口千藏, 佐々木理栄, 篠崎英司, 宮内輝, 上間達也, 吉岡靖生：化学療法に続いて化学放射線療法が施行され完全奏効を得たIV期下部直腸癌の1例. 日本放射線腫瘍学会第35回学術大会; 2022年度 2022.11, 広島. [一般口演]
13. 小口正彦：人工知能を有する統合がん診療支援システム(SIPAIH22D04).AIホスピタル成果発表シンポジウム2022; 2022年度 2022.12, 東京.  [口述発表]
14. 小口正彦：がんゲノム診療のためのAIホスピタル：統合がんデータベース構築. ゲノム医療推進研究会; 2022年度 2023.02, 東京.  [口述発表]

1. 吉岡靖生. (Webinar)：TrueBeam + ExacTrac 4台体制によるスピーディ/正確/安定のハイボリュームセンター運用〜医師の立場から〜. Varian Live! 6. 2023.1. オンライン開催
2. 吉岡靖生. 金マーカーを用いた寡分割外照射の最前線. 第110回日本泌尿器科学会総会. 2023.4.神戸.
3. 吉岡靖生. High-dose-rate Brachytherapy: Ready for Prime Time? 日本放射線腫瘍学会小線源治療部会第25回学術大会. 2023.5.神戸.
4. Yoshioka Y. Role of MR in Radiosurgery. APJI: The 1st Varian Radiosurgery Forum on Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT). 2023.9.東京.
5. 吉岡靖生. 進行前立腺がんに対する放射線治療の適用法と求められる画像診断. 第61回日本癌治療学会学術集会. 2023.10.横浜.
6. 吉岡靖生.：寡分割照射を理解するのに必要な基礎知識. 第51回日本放射線技術学会秋季学術大会. 2023.10.名古屋.
7. 吉岡靖生.：前立腺癌. 日本放射線腫瘍学会第36回学術大会. 2023.11.横浜.
8. 吉岡靖生.：ハイドロゲルスペーサーの安全な留置と効果的な治療計画. 日本放射線腫瘍学会第36回学術大会. 2023.12.横浜.
9. 芹澤慈子、阿武和、下谷内奈々、徳増健二、原田亜里咲、田口千蔵、浅利崇生、利安隆史、吉岡靖生：骨転移に対する体幹部定位放射線治療（SBRT）の有用性と安全性の検討.第36回.日本放射線腫瘍学会高精度放射線外部照射部会学術大会.2023.3.東京
10. 芹澤慈子、阿武和、下谷内奈々、徳増健二、原田亜里咲、田口千蔵、浅利崇生、利安隆史、吉岡靖生：前立腺癌IMRTにおける金マーカーを用いたIGRTと非IGRTとの比較. 日本放射線腫瘍学会第36回学術大会.2023.11-12.横浜

1. 吉岡靖生. 前立腺癌のhigh-dose-rate (HDR) brachytherapy：線量と技術の標準化により至高の放射線治療へ. 日本放射線腫瘍学会小線源治療部会第26回学術大会. 2024.05. 高崎.  [ランチョンセミナー講演]
2. 吉岡靖生. 前立腺がんに対する放射線治療：PACE trialsから読み解く前立腺SBRTの今後.
   第5回山梨・静岡放射線治療研究会. 2024.05. 沼津. [特別講演]
3. 利安隆史. 中咽頭癌に対する治療戦略：放射線治療医の立場から. 第48回日本頭頸部癌学会. 2024.06. 浜松. [シンポジウム]
4. 利安隆史, 中村聡明, 伊藤芳紀, 中村直樹, 齊藤吉弘, 高橋聡, 太田陽介, 稲田正浩, 村上祐司, 西村恭昌, 古平毅. T1-2N0-1M0中咽頭癌に対する強度変調放射線治療(IMRT)の多施設共同単群検証的試験(JCOG1208) 第48回日本頭頸部癌学会. 2024.06. 浜松. [口演]
5. 吉岡靖生. オリゴメタスタシスに対する放射線治療：定位照射によるablativeな転移巣治療.
   第49回日本外科系連合学会学術集会. 2024.06. 東京. [シンポジウム]
6. Yoshioka, Y. A modern clinical workflow of automated organs at risk contouring in radiotherapy treatment planning. AI utilization in our radiotherapy practice. The 9th Japan-Taiwan Radiation Oncology Symposium. 2024.08. 札幌. [招待講演]
7. 吉岡靖生. 前立腺がんへの組織内照射 良好な治療成績の理由. 第25回放射線腫瘍学夏季セミナー. 2024.08. 奈良. [教育講演]
8. 田口千蔵. 集学的治療における放射線治療の役割とストーマ管理. 第55回東京ストーマリハビリテーション研究会. 2024.09. 東京. [講演]
9. 原田亜里咲. 乳癌腋窩リンパ節郭清省略時における放射線治療の考え方. 第26回SNNS研究会学術集会. 2024.10. 東京. [シンポジウム]
10. 原田亜里咲. 乳癌腋窩リンパ節郭清省略時における放射線治療の考え方. 第26回SNNS研究会学術集会. 2024.10. 東京. [シンポジウム]
11. 吉岡靖生. mHSPC/mCRPCにおける原発巣/転移巣に対する放射線治療の意義. 第62回日本癌治療学会学術集会. 2024.10. 福岡. [シンポジウム]
12. Yoshioka, Y. Role of radiotherapy to the primary or to the metastases in metastatic prostate cancer.
    The 19th National Meeting of Chinese Society for Radiation Oncology (CSTRO). 2024.11. Beijing, China. [招待講演]
13. 利安隆史. 涙嚢部-鼻涙管のHPV関連扁平上皮癌に対するIMRTを用いた同時化学放射線療法の成績. 日本放射線腫瘍学会第37回学術大会. 2024.11. 横浜. [口演]
14. 吉岡靖生. 前立腺 SO vs noSO 定位 vs ブラキー. 日本放射線腫瘍学会第37回学術大会; 2024年度 2024.11, 横浜市. [座長]
15. 吉岡靖生. がんセンターにおける「Radixact」の役割と課題. 日本放射線腫瘍学会第37回学術大会. 2024.11. 横浜. [座長]
16. 芹澤慈子. 前立腺癌IMRTにおいてネオアジュバントアンドロゲン除去療法が有害事象に及ぼす影響. 日本放射線腫瘍学会第37回学術大会. 2024.11. 横浜. [ポスター発表]
17. 青木秀梨. 放射線治療をメジャー科にする?ダイバーシティが目指すものは. 日本放射線腫瘍学会第37回学術大会. 2024.11. 横浜. [セッション]
18. 吉岡靖生. 放射線治療の技術と腫瘍学〜がん研有明病院の現状紹介と将来への議論〜. 山口県放射線治療セミナー（株式会社バリアンメディカルシステムズ主催、山口県放射線治療セミナー後援）. 2024.3. 山口.

1. Nakajima N, Oguchi M, Kumai Y, Yoshida M, Inoda H, Yoshioka Y, Iwase T, Ito Y, Akiyama F, Ohno S. Clinical outcomes and prognostic factors in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy followed by surgery and postmastectomy radiation therapy in the modern treatment era. Adv Radiat Oncol　2018;3:271–279
2. Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, Lin SH. Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis. Radiat Oncol. 2018;13:258.
3. Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, Lin SH. Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis. Clin Lung Cancer. 2018;19:e885-e891.
4. Suzuki R, Lin SH, Wei X, Allen PK, Welsh JW, Byers LA, Komaki R. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol. 2018;126:499-505.
5. Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, Lin SH. Hematologic variables associated with brain failure in patients with small-cell lung cancer. Radiother Oncol. 2018;128:505-512.
6. Suzuki R, Komaki R. Is prophylactic cranial irradiation indicated for patients with extensive-stage small cell lung cancer with a complete response to first-line treatment? Radiother Oncol. Radiother Oncol. 2018;127:339-343.
7. Koike Y, Sumida I, Mizuno H, Shiomi H, Kurosu K, Ota S, Yoshioka Y, Suzuki O, Tamari K, Ogawa K. Dosimetric impact of intra-fraction prostate motion under a tumour-tracking system in hypofractionated robotic radiosurgery. PLoS One 2018;13: e0195296
8. Yamazaki H, Masui K, Suzuki G, Nakamura S, Shimizu D, Nishikawa T, Okabe H, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K. High-dose-rate brachytherapy monotherapy versus image-guided intensity-modulated radiotherapy with helical tomotherapy for patients with localized prostate cancer. Cancers (Basel) 2018;10:322
9. Murofushi KN, Kitamura N, Yoshioka Y, Sumi M, Ishikawa H, Oguchi M, Sakurai H. A clinical evaluation of American Brachytherapy Society consensus guideline for bulky vaginal mass in gynecological cancer. Int J Gynecol Cancer 2018;28:1438–1445
10. Yamazaki H, Masui K, Suzuki G, Nakamura S, Aibe N, Shimizu D, Nishikawa T, Okabe H, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K. Radiothrerapy for elderly patients aged ≥75 years with clinically localized prostate cancer-Is there a role of brachytherapy? J Clin Med 2018;7:424
11. Yamazaki H, Masui K, Suzuki G, Nakamura S, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K. Comparison of three moderate fractionated schedules employed in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer. Radiother Oncol 2018;129:370–376
12. Kanayama N, Kierkels RGJ, Schaaf A, Steenbakkers RJHM, Yoshioka Y, Nishiyama K, Fujii T, Ogawa K, Langendijk JA, Teshima T. External validation of a multifactorial normal tissue complication probability model for tube feeding dependence at 6smonths after definitive radiotherapy for head and neck cancer. Radiother Oncol 2018;129:403–408
13. Murofushi KN, Nakajima M, Tomita T, Sumi M, Yoshioka Y, Oguchi M, Sakurai H. Impact of visual feedback on dose-volume histograms for organs at risk in postoperative radiotherapy with deep inspiration breath-holding for patients treated with breast-conserving therapy: a planning study. Breast Cancer 2018;25:656–662
14. Varnava M, Sumida I, Mizuno H, Shiomi H, Suzuki O, Yoshioka Y, Ogawa K. A new plan quality objective function for determining optimal collimator combinations in prostate cancer treatment with stereotactic body radiation therapy using CyberKnife. PLoS One 2018;13:e0208086.
15. Yamaguchi M, Oguchi M, Suzuki R. Extranodal NK/T-cell lymphoma: Updates in biology and management strategies. Best Pract Res Clin Haematol. 2018;31(3):315-321.
16. Yoshida K, Otani Y, Nose T, Yoden E, Asahi S, Tsukiyama I, Dokiya T, Saeki T, Fukuda I, Sekine H, Kumazaki Y, Takahashi T, Kotsuma T, Masuda N, Nakashima K, Matsumura T, Nakagawa S, Tachiiri S, Moriguchi Y, Itami J, Oguchi M. Case report of a dose-volume histogram analysis of rib fracture after accelerated partial breast irradiation: interim analysis of a Japanese prospective multi-institutional feasibility study. J Contemp Brachytherapy. 2018;10(3):274-278.
17. Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood. 2018;131(23):2528-2540.
18. Yamaguchi M, Suzuki R, Kim SJ, Ko YH, Oguchi M, Asano N, Miyazaki K, Terui Y, Kubota N, Maeda T, Kobayashi Y, Amaki J, Soejima T, Saito B, Shimoda E, Fukuhara N, Tsukamoto N, Shimada K, Choi I, Utsumi T, Ejima Y, Kim WS, Katayama N. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. Cancer Sci. 2018;109(6):2056-2062.
19. Ishibashi N, Soejima T, Kawaguchi H, Akiba T, Hasegawa M, Isobe K, Ito H, Imai M, Ejima Y, Hata M, Sasai K, Shimoda E, Maebayashi T, Oguchi M, Akimoto T; Japanese Radiation Oncology Study Group. National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan: survey of the Japanese Radiation Oncology Study Group (JROSG). J Radiat Res. 2018;59(4):477-483.
20. Ng AK, Yahalom J, Goda JS, Constine LS, Pinnix CC, Kelsey CR, Hoppe B, Oguchi M, Suh CO, Wirth A, Qi S, Davies A, Moskowitz CH, Laskar S, Li Y, Mauch PM, Specht L, Illidge T. Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;100(3):652-669.
21. Tsuyama N, Asaka R, Dobashi A, Baba S, Mishima Y, Ueda K, Oguchi M, Tsuji H, Hatake K, Takeuchi K. Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation. Hematol Oncol. 2018;36(1):328-335.

1. Yoshioka Y, Itami J, Oguchi M, Nakano T. Preface. In: Yoshioka Y, Itami J, Oguchi M, Nakano T (eds.). Brachytherapy: Techniques and Evidences. Springer Nature Singapore 2019, vii
2. Yoshioka Y, Sumi M, Oguchi M. High-dose-rate brachytherapy as monotherapy for prostate cancer. In: Yoshioka Y, Itami J, Oguchi M, Nakano T (eds.). Brachytherapy: Techniques and Evidences. Springer Nature Singapore 2019, pp181–197
3. Suzuki R, Wei X, Allen PK, Cox JD, Komaki R, Lin SH. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer. Clin Lung Cancer. 2019;20:117-123.
4. Yamazaki H, Masui K, Suzuki G, Nakamura S, Yamada K, Okihara K, Shiraishi T, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer. Radiother Oncol 2019;132:162–170
5. Yamazaki H, Masui K, Suzuki G, Nakamura S, Aibe N, Shimizu D, Yamada K, Okihara K, Shiraishi T, Kotsuma T, Yoshida K, Tanaka E, Otani K, Yoshioka Y, Ogawa K, Nishikawa T, Okabe H. Effect of androgen deprivation therapy on other-cause of mortality in elderly patients with clinically localized prostate cancer treated with modern radiotherapy: Is there a negative impact? J Clin Med 2019;8:338
6. Yamazaki H, Masui K, Suzuki G, Nakamura S, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K. Influence of transitioning of planning techniques in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer from two- to three-dimensional planning. Brachytherapy 2019;18:589–597
7. Morimoto M, Bijl HP, Schaaf AVD, Xu CJ, Steenbakkers RJHM, Chouvalova O, Yoshioka Y, Teshima T, Langendijk JA. Development of normal tissue complication probability model for trismus in head and neck cancer patients treated with radiotherapy: The role of dosimetric and clinical factors. Anticancer Res 2019;39:6787–6798
8. Tominaga T, Akiyoshi T, Yamamoto N, Taguchi S, Mori S, Nagasaki T, Fukunaga Y, Ueno M. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. PLoS One. 2019;14(2):e0212978.
9. Konishi T, Shinozaki E, Murofushi K, Taguchi S, Fukunaga Y, Nagayama S, Fujimoto Y, Akiyoshi T, Nagasaki T, Suenaga M, Chino A, Kawachi H, Yamamoto N, Ishikawa Y, Oguchi M, Ishizuka N, Ueno M, Yamaguchi K. Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer. Ann Surg Oncol. 2019;26(8):2507-2513.
10. Sapienza LG, Ning MS, Taguchi S, Calsavara VF, Pellizzon ACA, Gomes MJL, Kowalski LP, Baiocchi G. Altered-fractionation radiotherapy improves local control in early-stage glottic carcinoma: A systematic review and meta-analysis of 1762 patients. Oral Oncol. 2019;93:8-14.
11. Takano S, Omura M, Suzuki R, Tayama Y, Matsui K, Hashimoto H, Hongo H, Nagata H, Tanaka K, Hata M, Inoue T. Intensity-modulated radiation therapy using TomoDirect for postoperative radiation of left-sided breast cancer including lymph node area: comparison with TomoHelical and three-dimensional conformal radiation therapy. J Radiat Res. 2019;60:694-704.
12. Yamauchi C, Yoshimura M, Sekiguchi K, Hamamoto Y, Nakajima N, Sanuki N, Ogo E, Oguchi M, Saji S, Iwata H. The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27(1):9-16.
13. Kawaguchi H, Soejima T, Ishibashi N, Akiba T, Hasegawa M, Isobe K, Ito H, Imai M, Ejima Y, Hata M, Sasai K, Shimoda E, Oguchi M, Akimoto T. National survey on total-body irradiation prior to reduced-intensity stem cell transplantation in Japan: The Japanese Radiation Oncology Study Group. J Radiat Res. 2019;60(5):579-585.
14. Kondo K, Matsusaka S, Ishihara S, Horie H, Uehara K, Oguchi M, Murafushi K, Ueno M, Mizunuma N, Shimbo T, Kato D, Okuda J, Hashiguchi Y, Nakazawa M, Sunami E, Kawai K, Yamashita H, Okada T, Ishikawa Y, Fujii M, Nakajima T. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial). Radiother Oncol. 2019;134:199-203.
15. Yamaguchi M, Suzuki R, Miyazaki K, Amaki J, Takizawa J, Sekiguchi N, Kinoshita S, Tomita N, Wada H, Kobayashi Y, Niitsu N, Ando T, Maeda T, Saito B, Matsuoka H, Sakai R, Kubota N, Masaki Y, Kameoka Y, Asano N, Oguchi M, Katayama N. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin. Ann Hematol. 2019;98(7):1647-1655.
16. Binkley MS, Brady JL, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Ahmed S, MacManus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova YM, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Mikhaeel NG, Hoppe RT. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. Int J Radiat Oncol Biol Phys. 2019;104(3):522-529.
17. Tsuyama N, Yokoyama M, Fujisaki J, Oguchi M, Terui Y, Takeuchi K. Villous colonization (glove balloon sign): A histopathological diagnostic marker for follicular lymphomas with duodenal involvement including duodenal-type follicular lymphoma. Pathol Int. 2019;69(1):48-50.
18. Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Hoppe RT, Mikhaeel NG. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019;133(3):237-245.

1. Suzuki R, Yoshida M, Oguchi M, Yoshioka Y, Tokumasu K, Osako T, Ono S, Ueno T, Miyagi Y. Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins. J Radiat Res. 2020 May 22;61(3):440-446. doi: 10.1093/jrr/rraa005.
2. Suzuki R, Yoshida M, Oguchi M, Yoshioka Y, Tokumasu K, Osako T, Ono S, Ueno T, Miyagi Y. Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins. J Radiat Res. 2020; 61(3): 440–446.
3. Sasamura K, Suzuki R, Kozuka T, Yoshimura R, Yoshioka Y, Oguchi M. Outcomes after reirradiation of spinal metastasis with stereotactic body radiation therapy (SBRT): a retrospective single institutional study. J Radiat Res. 2020;61(6):929-934.
4. 篠村一磨、吉岡靖生、小口正彦　【画像診断医にも知ってほしい放射線治療:画像が担う役割】画像情報の利用　治療計画立案からフォローアップまで　前立腺癌 臨床画像36巻2号166-174.2020
5. Murofushi KN, Yoshioka Y, Ishikawa H, Sumi M, Okumura T, Oguchi M, Sakurai H. Selection criteria and clinical outcomes of patients with asymmetrical cervical cancer treated with various high-dose-rate brachytherapy techniques. Anticancer Res 2020;40:999–1006
6. Uchida H, Hirata T, Otani K, Suzuki O, Oda M, Akino Y, Sumida I, Hatano K, Fujita K, Uemura M, Imamura R, Eino D, Yoshioka Y, Nonomura N, Ogawa K. Assessment of daily replanning and geometrical variation of high-dose-rate brachytherapy for the prostate. Anticancer Res 2020;40:1677–1682
7. Murofushi K, Yoshioka Y, Sumi M, Ishikawa H, Oguchi M, Sakurai H. Outcomes analysis of pre-brachytherapy MRI in patients with locally advanced cervical cancer. Int J Gynecol Cancer 2020;30:473–479
8. Nakamura R, Hirata T, Suzuki O, Otani K, Kai N, Hatano K, Fujita K, Uemura M, Imamura R, Tanaka K, Yoshioka Y, Nonomura N, Ogawa K. Stereotactic body radiotherapy using CyberKnife® for localized low- and intermediate-risk prostate cancer: Initial report on a phase I/II trial. Anticancer Res 2020;40:2053–2057
9. Kim H, Jeong H, Yamaguchi M, Sohn I, Yoon SE, Byeon S, Hur JY, Koh Y, Yoon SS, Kim EJ, Oguchi M, Miyazaki K, Taguchi S, Yoon DH, Cho J, Ko YH, Kim SJ, Suzuki R, Kim WS. Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood. 2020;136(22):2548-2556.
10. Nakanishi R, Akiyoshi T, Toda S, Murakami Y, Taguchi S, Oba K, Hanaoka Y, Nagasaki T, Yamaguchi T, Konishi T, Matoba S, Ueno M, Fukunaga Y, Kuroyanagi H. Radiomics Approach Outperforms Diameter Criteria for Predicting Pathological Lateral Lymph Node Metastasis After Neoadjuvant (Chemo)Radiotherapy in Advanced Low Rectal Cancer. Ann Surg Oncol. 2020;27(11):4273-4283.
11. Kim H, Jeong H, Yamaguchi M, Sohn I, Yoon SE, Byeon S, Hur JY, Koh Y, Yoon SS, Kim EJ, Oguchi M, Miyazaki K, Taguchi S, Yoon DH, Cho J, Ko YH, Kim SJ, Suzuki R, Kim WS. Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood. 2020;136(22):2548-2556.
12. Yamano T, Tomita N, Sato T, Hayakawa K, Kamikonya N, Matoba S, Uki A, Baba H, Oya N, Hasegawa H, Shigematsu N, Hiraoka M, Shimada M, Noda M, Sakai Y, Sato H, Saegusa M, Takeuchi M, Oguchi M, Oya M, Watanabe M. Influence of chemoradiotherapy on nutritional status in locally advanced rectal cancer: Prospective multicenter study. Nutrition. 2020;77:110807.

1. Shou H, Yoshioka Y, Yuan S, Lou H, Ni J. Association of pretreatment SUV max of cervix and SCC-antigen with FIGO2018 stage in Stage IIB-IVB squamous cervical cancer and relationship to prognosis. Int J Gynaecol Obstet. 2021 Jan;152(1):112-117.
2. Ito M, Sasamura K, Takase Y, Kotsuma T, Oshima Y, Minami Y, Suzuki J, Tanaka E, Ohashi W, Oguchi M, Okuda T, Suzuki K, Yoshioka Y. Comparison of physician-recorded toxicities and patient-reported outcomes of five different radiotherapy methods for prostate cancer. Anticancer Res. 2021 May;41(5):2523-2531.
3. Takemoto N, Seo Y, Nakahara S, Yoshioka Y, Teshima T, Fujii T, Isohashi F, Otani K, Yoshii T, Takenaka Y, Suzuki M, Fukusumi T, Hanamoto A, Yasui T, Michiba T, Yamamoto Y, Shimamoto S, Tanaka H, Tatsumi M, Ogawa K, Inohara H. Radiation therapy alone for human papillomavirus-related squamous cell carcinoma of the oropharynx: a single-arm, phase 2 study. Int J Radiat Oncol Biol Phys. 2021 June;110(2):403-411.
4. Yoshioka Y. Research work of Prof. Yoshioka on high-dose-rate brachytherapy monotherapy for prostate cancer. Impact. 2021 June;5(3):25-27.
5. Ito M, Yoshioka Y, Takase Y, Suzuki J, Matsunaga T, Takahashi H, Takeuchi A, Adachi S, Abe S, Oshima Y, Ohtakara K, Suzuki K, Okuda T. Stereotactic body radiation therapy for Japanese patients with localized prostate cancer: 2-year results and predictive factors for acute genitourinary toxicities. Jpn J Clin Oncol. 2021 Aug 1;51(8):1253-1260.
6. Murakami N, Ando K, Murata M, Murata K, Ohno T, Aoshika T, Kato S, Okonogi N, Saito AI, Kim JY, Kumai Y, Yoshioka Y, Sekii S, Tsujino K, Lowanichkiattikul C, Pattaranutaporn P, Kaneyasu Y, Nakagawa T, Watanabe M, Uno T, Umezawa R, Jingu K, Kanemoto A, Wakatsuki M, Shirai K, Igaki H, Itami J. Why not de-intensification for uterine cervical cancer? Gynecol Oncol. 2021 Oct;163(1):105-109.
7. Shimoyachi N, Yoshioka Y, Sasamura K, Yonese J, Yamamoto S, Yuasa T, Soyano T, Kozuka T, Oguchi M. Comparison between dose-escalated intensity modulated radiation therapy and 3-dimensional conformal radiation therapy for salvage radiation therapy after prostatectomy. Adv Radiat Oncol, 2021 Nov;6:100753.
8. Kanie, Y., Okamura, A., Asari, T., Maruyama, S., Sakamoto, K., Fujiwara, D., Kanamori, J., Imamura, Y., Ishiyama, A., Yoshio, T., Tsuchida, T., Chin, K., Watanabe, M. Additional treatment following noncurative endoscopic resection for esophageal squamous cell carcinoma: A comparison of outcomes between esophagectomy and chemoradiotherapy.Ann. Surg. Oncol.: 28,8428-8435, 2021
9. Kanie, Y., Okamura, A., Asari, T., Ishiyama, A., Yoshio, T., Tsuchida, T., Chin, K., Watanabe, M.ASO author reflections: esophagectomy or chemoradiotherapy, that is the question: additional treatment following noncurative endoscopic resection for esophageal squamous cell carcinoma.Ann. Surg. Oncol.: 28,8436-8437, 2021
10. Kanie, Y., Okamura, A., Asari, T., Maruyama, S., Sakamoto, K., Fujiwara, D., Kanamori, J., Imamura, Y., Ishiyama, A., Yoshio, T., Tsuchida, T., Chin, K., Watanabe, M.ASO visual abstract: Additional treatment following noncurative endoscopic resection for esophageal squamous cell carcinoma: A comparison of outcomes between esophagectomy and chemoradiotherapy.Ann. Surg. Oncol.: 28,477-478, 2021
11. Otake, R., Okamura, A., Yamashita, K., Imamura, Y., Kanamori, J., Kozuki, R., Takahashi, K., Toihata, T., Yamamoto, N., Asari, T., Mine, S., Watanabe, M.Efficacy of postoperative radiotherapy in esophageal squamous cell carcinoma patients with positive circumferential resection margin.Esophagus, 18 (2): 288-295, 2021.4
12. Sasamura K, Soyano T, Kozuka T, Yuasa T, Yamamoto S, Yonese J, Oguchi M, Yoshimura R, Yoshioka Y. Outcomes of intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: a single-institutional study. Jpn J Clin Oncol. 2021 Oct 23;hyab167. Online ahead of print.
13. Qi SN, Li YX, Specht L, Oguchi M, Tsang R, Ng A, Suh CO, Ricardi U, Mac Manus M, Dabaja B, Yahalom J. Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):1064-1081.
14. Yamauchi C, Yoshimura M, Sekiguchi K, Hamamoto Y, Nakajima N, Sanuki N, Ogo E, Oguchi M, Saji S, Iwata H. Correction to: The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition. Breast Cancer. 2021 Jul;28(4):988.
15. 吉岡靖生（聞き手：池脇克則）：前立腺がんの治療法. ドクターサロン（ISSN 0389-7303）2021;65(5):357-360
16. 吉岡靖生,中島大：がん研究会有明病院のRapidArcの現状：臨床面と物理的側面からのUpdate. varian RT REPORT. INNERVISION 2021;36(5):94-95
17. 吉岡靖生,伊藤誠,高瀬裕樹,鈴木淳司,奥田隆仁,小口正彦. 前立腺癌に対する体幹部定位放射線治療. 定位的放射線治療 2021;25:117-126
18. 吉岡靖生：総論：放射線治療のブレイクスルーと近未来. INNERVISION 2021;36(11):53-55
19. 吉岡靖生,小口正彦：小線源治療のエビデンスと課題. 腫瘍内科 2021;28(5):484-489
20. 吉岡靖生: 効果的にパワーを集中 放射線治療. 肺がん 最新治療. NHKテキスト きょうの健康. 2021;12:30-33
21. 小口正彦, 鈴木一洋, 佐野武, 大野真司：AIホスピタルによる高度診断・治療システムに参加して：人工知能を有する統合がん診療支援システムの開発.腫瘍内科, 27 (1): 120-126, 2021.1
22. 小口正彦, 渡邊雅之, 鈴木一洋, 月村駿, 佐野武：最先端の消化器外科クリニカルパス：総論　AI時代のクリニカルパス.外科, 83 (1): 14-17, 2021.1

1. Akiyoshi T, Shinozaki E, Taguchi S, Chino A, Hiratsuka M, Tominaga T, Nonaka T, Toda S, Matoba S, Matsui  S, Okabayashi K, Mukai T, Hiyoshi Y, Yamaguchi T, Nagasaki T, Yamaguchi K, Ueno M, Kuroyanagi H, Fukunaga Y, Ishizuka N, Konishi T., Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).BMJ Open, 12 (3): e055140, 2022
2. Inada M, Nishimura Y, Ishikura S, Ishikawa K, Murakami N, Kodaira T, Ito Y, Tsuchiya K, Murakami Y, Saito J, Akimoto T, Nakata K, Yoshimura M, Teshima T, Toshiyasu T, Ota Y, Minemura T, Shimizu H, Hiraoka M. Organs-at-risk dose constraints in head and neck intensity-modulated radiation therapy using a dataset from a multi-institutional clinical trial (JCOG1015A1). Radiat. Oncol., 17 (1): 133, 2022
3. Kawamura H, Nakamura K, Yoshioka Y, Itasaka S, Tomita N, Onishi M, Iwata H, Aizawa T, Kikuchi K, Nagata K, Nakamura K, Nishioka K, Ishiyama H, Ueno S, Kokubo M, Yamazaki H, Watanabe K, Toyoda T, Akimoto T. Radiotherapy for ductal carcinoma of the prostate: an analysis based on the Japanese radiation oncology study group survey. Jpn. J. Clin. Oncol.: in press, 2022
4. Miyazaki K, Suzuki R, Oguchi M, Taguchi S, Amaki J, Takeshi M, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y, Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Ejima Y, Katayama N, Yamaguchi M. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma. Hematol. Oncol., 40 (4): 667-677, 2022
5. Murakami N, Ando K, Murata M, Murata K, Ohno T, Aoshika T, Kato S, Okonogi N, Saito A I, Kim J Y, Yoshioka Y, Sekii S, Tsujino K, Lowanichkiattikul C, Pattaranutaporn P, Kaneyasu Y, Nakagawa T, Watanabe M, Uno T, Umezawa R, Jingu K, Kanemoto A, Wakatsuki M, Shirai K, Igaki H, Itami J. An Asian multi-national multi-institutional retrospective study comparing intracavitary versus the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical carcinoma. J. Radiat. Res., 63 (3): 412-427, 2022
6. Murakami Y, Soyano T, Kozuka T, Ushijima M, Koizumi Y, Miyauch H, Kaneko M, Nakano M, Kamima T, Hashimoto T, Yoshioka Y, Oguchi M. Dose-based radiomic analysis (dosiomics) for intensity-modulated radiotherapy in patients with prostate cancer: Correlation between planned dose distribution and biochemical failure.Int. J. Radiat. Oncol. Biol. Phys., 112 (1): 247-259, 2022
7. Murakami Y, Murakami Y, Kamima T, Oguchi M, Abo N, Takahashi T, Kaneko M, Nakano M, Matsubayashi F, Harada A, Taguchi S, Hashimoto T, Yoshioka Y. Dosimetric comparison between three-dimensional conformal radiotherapy followed by electron beam boost and volumetric modulated arc therapy using concomitant boost for the heart and cardiac segments in patients with left-sided breast cancer at risk for radiation-induced cardiac toxicity. Phys. Med., 95: 126-132, 2022
8. Murakami N, Watanabe M, Uno T, Sekii S, Tsujino K, Kasamatsu T, Machitori Y, Aoshika T, Kato S, Hirowatari H, Kaneyasu Y, Nakagawa T, Ikushima H, Ando K, Murata M, Yoshida K, Yoshioka H, Murata  K, Ohno T, Okonogi N, Saito A, Ichikawa M, Okuda T, Tsuchida K, Sakurai H, Yoshimura R, Yoshioka Y, Yorozu A, Okamoto H, Inaba K, Kato T, Igaki H, Itami J. Large volume was associated with increased risk of acute non-hematologic adverse events in the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer: preliminary results of prospective phase I/II clinical trial. Jon. J. Clin. Oncol., 52 (8): 851-860, 2022
9. Murakami N, Watanabe M, Uno T, Sekii S, Tsujino K, Kasamatsu T, Machitori Y, Aoshika T, Kato S, Hirowatari H, Kaneyasu Y, Nakagawa T, Ikushima H, Ando K, Murata M, Yoshida K, Yoshioka H, Murata  K, Ohno T, Okonogi N, Saito A I, Ichikawa M, Okuda T, Tsuchida K, Sakurai H, Yoshimura R, Yoshioka Y, Yorozu A, Kunitake N, Okamoto H, Inaba K, Kato T, Igaki H, Itami J. Phase I/II prospective clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer. J. Gynecol. Oncol.: in press, 2022
10. Naito S, Yoshio T, Ishiyama A, Tsuchida T, Tokura J, Namikawa K, Tokai Y, Yoshimizu S, Horiuchi Y, Hirasawa T, Asari T, Mine S, Watanabe M, Ogura M, Chin K, Fukuzawa M, Itoi T, Fujisaki J. Long-term outcomes of esophageal squamous cell carcinoma with invasion depth of pathological T1a-muscularis mucosae and T1b-submucosa by endoscopic resection followed by appropriate additional treatment. Dig. Endosc., 34 (4): 793-804, 2022
11. Okamura A, Yoshimizu S, Kanamori J, Imamura Y, Asari T, Nakayama I, Ogura M, Ishiyama A, Yoshio T, Chin K, Fujisaki J, Watanabe M. Treatment strategy for esophageal squamous cell carcinoma with endoscopic intramural metastasis. Cureus, 14 (3): e23028, 2022
12. Okonogi N, Murakami N, Ando K, Murata M, Murata K, Aoshika T, Kato S, Saito A I, Kim,J Y, Yoshioka Y, Sekii S, Tsujino K, Lowanichkiattikul C, Pattaranutaporn P, Kaneyasu Y, Nakagawa T, Watanabe M, Uno T, Umezawa R, Jingu K, Kanemoto A, Wakatsuki M, Shirai K, Igaki H, Ohno T, Itami J. An Asian multi-national, multi-institutional, retrospective study on image-guided brachytherapy in cervical adenocarcinoma and adenosquamous carcinoma. J. Contemp. Brachytherapy, 14 (4): 311-320, 2022
13. Sakurai T, Takamatsu S, Shimoyachi N, Shibata S, Makino M, Ohashi S, Taima Y, Minamikawa R, Kumano T, Gabata T. Prediction of post-radiotherapy survival for bone metastases: a comparison of the 3-variable number of risk factors model with the new Katagiri scoring system. J. Radiat. Res., 63 (2): 303-311, 2022
14. Sasamura K, Soyano T, Kozuka T, Yuasa T, Yamamoto S, Yonese J, Oguchi M, Yoshimura R, Yoshioka Y. Outcomes of intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: a single-institutional study. Jpn. J. Clin. Oncol., 52 (2): 170-178, 2022
15. Suzuki K, Ikenoyama Y, Hirasawa T, Yoshimizu S, Horiuchi Y, Ishiyama A, Yoshio T, Taguchi S, Yoshioka Y, Fujisaki J. Clinical course and treatment of radiation-induced hemorrhagic gastritis: A case series study. Clin. J. Gastroenterol.: in press, 2022
16. Suzuki T, Okamura A, Watanabe M, Asari T, Nakayama I, Ogura M, Ooki A, Takahari D, Yamaguchi K, Chin K. Serum squamous cell carcinoma antigen is a predictive factor of outcomes in patients with locally advanced unresectable esophageal squamous cell carcinoma treated by definitive chemoradiotherapy. J. Cancer Metastasis Treat., 8: 5, 2022
17. Yoshida K, Nose T, Otani Y, Asahi S, Tsukiyama I, Dokiya T, Saeki T, Fukuda I, Sekine H, Kumazaki Y, Takahashi T, Kotsuma T, Masuda N, Yoden E, Nakashima K, Matsumura T, Nakagawa S, Tachiiri S, Moriguchi Y, Itami J, Oguchi M. A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using multicatheter interstitial brachytherapy: clinical results with a median follow-up of 60 months. Breast Cancer, 29 (4): 636-644, 2022
18. Yoshioka Y. The application and utility of radiotherapy planning MRI at the Cancer Institute Hospital of JFCR. MReadings: MR in RT 8th ed. (Low, D. ed.), ESTRO p.24-28,
19. 原田亜里咲: BRCA病的バリアントを有する乳癌患者に対し、乳房手術後の放射線療法は勧められるか？. 乳癌診療ガイドライン１；治療編 第5版 (日本乳癌学会編), 東京, 金原出版 p.460-462,  2022.
20. 吉岡靖生: 前立腺癌に対する高線量率組織内照射(HDR)の長期成績と最新状況. 臨床泌尿器科, 76 (8): 534-541, 2022
21. 吉岡靖生: 効果的にパワーを集中：放射線治療：肺がん最新治療(アンコール放送). NHKテキストきょうの健康, 2022年 (5月号): 54-55, 2022
22. 吉岡靖生: 頭頸部：高線量率(HDR)照射. 小線源治療部会ガイドラインに基づく密封小線源治療診療・物理QAマニュアル 第2版 (日本放射線腫瘍学会小線源治療部会編), 東京, 金原出版 p.80-87,
23. 田口千藏: 血液疾患のすべて：治療：放射線治療. 日本医師会雑誌, 151 (特別1): S151-S152, 2022
24. 田口千藏: 造血器腫瘍の治療開発におけるunanswered questions-エビデンスと今後の展望：未治療限局期濾胞性リンパ腫に対して放射線治療を選択すべきか. 血液内科, 85 (4): 457-461, 2022
25. 吉岡靖生,浅利崇生,村山重行,西村哲夫,笹平直樹,��橋祐: 胆道癌の放射線治療の最近の進歩. 胆道 2022;36(4):565-576.
26. 小口正彦, 鈴木一洋, 佐野武: がん研有明病院におけるAIホスピタルの取り組み：人工知能を有する統合がん診療支援システムの開発.医学のあゆみ, 282 (10): 932-937, 2022

1. Kawamura H, Nakamura K, Yoshioka Y, Itasaka S, Tomita N, Onishi M, Iwata H, Aizawa T, Kikuchi K, Nagata K, Nakamura K, Nishioka K, Ishiyama H, Ueno S, Kokubo M, Yamazaki H, Watanabe K, Toyoda T, Akimoto T; JROSG Working Subgroup of Urologic Oncology. Radiotherapy for ductal carcinoma of the prostate: an analysis based on the Japanese radiation oncology study group survey. Jpn J Clin Oncol. 2023 Jan 28;53(2):146-152.
2. Ito M, Yoshioka Y, Takase Y, Suzuki J, Takahashi H, Minami Y, Sakuragi A, Oshima Y, Okuda T, Suzuki K. Stereotactic body radiation therapy for prostate cancer: a study comparing 3-year genitourinary toxicity between CyberKnife and volumetric-modulated arc therapy by propensity score analysis. Radiat Oncol. 2023 Feb 23;18(1):39.
3. Yoshida S, Takahara T, Arita Y, Ito M, Hayakawa S, Oguchi T, Komai Y, Numao N, Yuasa T, Inoue M, Ushijima H, Kudo S, Shimano Y, Nakamura Y, Uchida Y, Uehara S, Tanaka H, Yaegashi H, Izumi K, Yokoyama M, Matsuoka Y, Yoshioka Y, Konishi K, Nakanishi K, Nagahara A, Hirakawa A, Koike R, Koga F, Nishimura K, Mizokami A, Yonese J, Kageyama Y, Yoshimura R, Fujii Y. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL). BMC Urol. 2023 Mar 6;23(1):33.
4. Suzuki K, Ikenoyama Y, Hirasawa T, Yoshimizu S, Horiuchi Y, Ishiyama A, Yoshio T, Taguchi S, Yoshioka Y, Fujisaki J. Clinical course and treatment of radiation-induced hemorrhagic gastritis: a case series study. Clin J Gastroenterol. 2023 Apr;16(2):152-158.
5. Murakami N, Watanabe M, Uno T, Sekii S, Tsujino K, Kasamatsu T, Machitori Y, Aoshika T, Kato S, Hirowatari H, Kaneyasu Y, Nakagawa T, Ikushima H, Ando K, Murata M, Yoshida K, Yoshioka H, Murata K, Ohno T, Okonogi N, Saito AI, Ichikawa M, Okuda T, Tsuchida K, Sakurai H, Yoshimura R, Yoshioka Y, Yorozu A, Kunitake N, Okamoto H, Inaba K, Kato T, Igaki H, Itami J. Phase I/II prospective clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer. J Gynecol Oncol. 2023 May;34(3):e24.
6. Omura K, Murakami Y, Hashimoto K, Takahashi H, Suzuki R, Yoshioka Y, Oguchi M, Ichinose J, Matsuura Y, Nakao M, Okumura S, Mun M. Detection of EGFR mutations in early-stage lung adenocarcinoma by machine learning-based radiomics. Transl Cancer Res. 2023 Apr 28;12(4):837-847.
7. Hirata T, Suzuki O, Otani K, Miyake A, Tamari K, Seo Y, Isohashi F, Kai N, Hatano K, Fujita K, Uemura M, Imamura R, Tamenaga S, Yoshino Y, Fumimoto Y, Yoshioka Y, Nonomura N, Ogawa K. Increased toxicities associated with dose escalation of stereotactic body radiation therapy in prostate cancer: results from a phase I/II study. Acta Oncol. 2023 May;62(5):488-494.
8. Soyano T, Kozuka T, Kashihara K, Murakami Y, Yonese J, Sasamura K, Shimoyachi N, Kashihara T, Yoshioka Y, Oguchi M. Intensity-modulated radiation therapy for intermediate-risk prostate cancer: does ADT still have an impact in the dose-escalated external beam radiation therapy era? Jpn J Clin Oncol. 2023 Jun 1;53(6):514-521.
9. Nakajima N, Isobe T, Furuyama Y, Tomita T, Kobayashi D, Mori Y, Takei H, Nagai Y, Ide Y, Murofushi KN, Nakajima M, Yoshioka Y. Analysis of source dwell position during treatment in brachytherapy using CT scout images. J Contemp Brachytherapy. 2023 Oct 30;15(5):357–364.
10. Yoshioka Y, Sasamura K, Ito M, Kaneko M, Takahashi T, Anno W, Shimoyachi N, Suzuki J, Okuda T, Kashihara T, Inaba K, Igaki H, Itami J. Treatment planning comparison of high-dose-rate brachytherapy vs. robotic and conventional stereotactic body radiotherapy for ultrahypofractionated treatment of prostate cancer. Phys Imaging Radiat Oncol. 2023:100445.
11. Hashimoto K, Murakami Y, Omura K, Takahashi H, Suzuki R, Yoshioka Y, Oguchi M, Ichinose J, Matsuura Y, Nakao M, Okumura S, Ninomiya H, Nishio M, Mun M. Prediction of tumor PD-L1 expression in resectable non-small cell lung cancer by machine learning models based on clinical and radiological features: performance comparison with preoperative biopsy. Clin Lung Cancer. 2023 Aug 11:S1525-7304(23)00155-9.
12. Yamaguchi T, Akiyoshi T, Fukunaga Y, Sakamoto T, Mukai T, Hiyoshi Y, Nagasaki T, Taguchi S, Chino A, Shinozaki E, Yamaguchi K, Konishi T. Adding induction chemotherapy before chemoradiotherapy with total mesorectal excision and selective lateral lymph node dissection for patients with poor-risk, locally advanced, mid-to-low rectal cancer may improve oncologic outcomes: A propensity score-matched analysis. Ann Surg Oncol. 2023 30 (8): 4716-4724.
13. Yamaguchi T, Akiyoshi T, Fukunaga Y, Sakamoto T, Mukai T, Hiyoshi Y, Nagasaki T, Taguchi S, Chino A, Shinozaki E, Yamaguchi K, Konishi T. ASO visual abstract: Adding induction chemotherapy before chemoradiotherapy with total mesorectal excision and selective lateral lymph node dissection in patients with poor-risk, locally advanced, mid-to-low rectal cancer may improve oncological outcomes: A propensity score-matched analysis. Ann Surg Oncol. 2023 30 (8): 4727-4728.
14. 吉岡靖生.：CQ10 高リスク前立腺癌に対する放射線療法として、永久挿入密封小線源療法（LDR）＋外照射（EBRT）＋ホルモン療法（tri-modality）は推奨されるか？ 総論9 放射線療法（組織内照射）. 日本泌尿器科学会,編: 前立腺癌診療ガイドライン2023年版. メディカルレビュー社. 大阪2023:106-111,195-201
15. 吉岡靖生.：腎・腎盂・尿管・膀胱・陰茎・尿道・精巣・前立腺. 井上俊彦,ほか編: 放射線治療学. 改訂7版. 南山堂. 東京2023:271-288
16. 吉岡靖生.：臨床小線源治療: 陰茎・尿道癌, 前立腺癌. 井上俊彦,ほか編: 放射線治療学. 改訂7版. 南山堂. 東京2023:383-384
17. 吉岡靖生, 利安隆史.：頭頸部腫瘍（口腔癌：舌以外）. 大西洋,ほか編: がん・放射線療法. 改訂第8版. 株式会社Gakken. 東京2023:800-806
18. 吉岡靖生, 渡邉詩織.：外照射療法の進歩. 臨床前立腺癌学. 日本臨牀（日本臨牀社）2023;81(Suppl 6):259-263

1. Hashimoto K, Murakami Y, Omura K, Takahashi H, Suzuki R, Yoshioka Y, Oguchi M, Ichinose J, Matsuura Y, Nakao M, Okumura S, Ninomiya H, Nishio M, Mun M. Prediction of Tumor PD-L1 Expression in Resectable Non-Small Cell Lung Cancer by Machine Learning Models Based on Clinical and Radiological Features: Performance Comparison With Preoperative Biopsy. Clin Lung Cancer. 2024 Jan;25(1):e26-e34.e6.
2. Ishibashi N, Ejima Y, Soejima T, Kawaguchi H, Taguchi S, Ito H, Shimizuguchi T, Isobe K, Hasegawa M, Sasai K, Imai M, Shimoda E, Kaizu H, Okano N, Imagumbai T, Akimoto T. Autologous Peripheral Blood Stem Cell Transplantation and Timing of Local Radiation Therapy in Patients With Malignant Lymphoma: Results of the Japanese Radiation Oncology Study Group Questionnaire Survey. Anticancer Res. 2024 Jul;44(7):3033-3041.
3. Kusumoto S, Munakata W, Machida R, Terauchi T, Onaya H, Oguchi M, Iida S, Nosaka K, Suzuki Y, Harada Y, Miyazaki K, Maruta M, Fukuhara N, Toubai T, Kubota N, Ohmachi K, Saito T, Rai S, Mizuno I, Fukuhara S, Takeuchi M, Tateishi U, Maruyama D, Tsukasaki K, Nagai H. Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305). Cancer Sci. 2024 Oct;115(10):3384-3393.
4. Noguchi T, Akiyoshi T, Sakamoto T, Matsui S, Mukai T, Yamaguchi T, Koyama M, Taguchi S, Shinozaki E, Kawachi H, Fukunaga Y. Features of Lateral Pelvic Lymph Nodes Associated With Pathological Involvement After Total Neoadjuvant Therapy in Patients Undergoing Lateral Pelvic Lymph Node Dissection. Dis Colon Rectum. 2025 Mar 1;68(3):316-326.
5. Sato Y, Takahashi S, Toshiyasu T, Tsuji H, Hanai N, Homma A. Squamous cell carcinoma of the eyelid. Jpn J Clin Oncol. 2024 Jan 7;54(1):4-12.
6. Serizawa I, Kozuka T, Soyano T, Sasamura K, Kamima T, Kunogi H, Kurihara N, Numao N, Yamamoto S, Yonese J, Yoshioka Y. Clinical and Dosimetric Comparison Between Non-image Guided Radiation Therapy and Fiducial-Based Image Guided Radiation Therapy With or Without Reduced Margin in Intensity Modulated Radiation Therapy for Prostate Cancer. Adv Radiat Oncol. 2024 Aug 24;9(10):101612.
7. Serizawa I, Kozuka T, Soyano T, Sasamura K, Kamima T, Kunogi H, Numao N, Yamamoto S, Yonese J, Yoshioka Y. Impact of neoadjuvant androgen deprivation therapy on toxicity in intensity-modulated radiation therapy for prostate cancer. J Radiat Res. 2024 Sep 24;65(5):693-700.
8. Takahashi R, Osumi H, Wakatsuki T, Yamamoto N, Taguchi S, Nakayama I, Ooki A, Ogura M, Takahari D, Chin K, Yamaguchi K, Shinozaki E. Clinical outcomes and prognostic factors of concurrent chemoradiotherapy for anal squamous cell carcinoma in Japan. Int J Clin Oncol. 2024 Aug;29(8):1161-1172.
9. 吉岡靖生. 臨床腎・泌尿器癌(上) 基礎・臨床研究の進歩 ：腎癌の治療　放射線療法　その他の放射線療法(緩和照射を含む) 日本臨床, 82 (増刊8 臨床腎・泌尿器癌(上)): 412-417, 2024
10. 上田和彦，小口正彦. 肺がんCT検診とartificial intelligence（AI）. 呼吸器内科, 2025 Jan; 47(1).
11. 佐々木理栄, 田口千藏, 篠崎英司, 宮内輝, 上間達也, 吉岡靖生. 薬物療法後の原発巣残存に対して根治的化学放射線療法が施行され完全奏効を得た切除不能IV期下部直腸癌の1例. 日本放射線科専門医会・医会学術雑誌, 4: 20-24, 2024

1. Murakami Y, Matsubayashi F, Magome T, Takahashi R, Arima M, Kamima T, Nakano M, Sato T, Yoshioka Y, Oguchi M. Potential of jaw tracking technique in flattening filter-free beam for lung stereotactic body radiation therapy. American Association of Physicists in Medicine. Aug. 2018. Nashville, USA.

1. Murakami Y, Magome T, Nakano M, Sato T, Yoshioka Y, Oguchi M. Effect of prostatic calcification on radiomic features extracted from computed tomography (CT). The Taiwan Society of Radiological Technologists (TWSRT) and the International Conference of Medical Imaging. Mar. 2019. Taichung, Taiwan.
2. Murakami Y, Magome T, Mizutani T, Sato T, Yoshioka Y, Oguchi M. Potential of radiomic feature related to prostatic calcifications for the machine learning based prediction of biochemical recurrence in prostate cancer patient. American Society for Radiation Oncology. Nov. 2019. Chicago, USA.
3. Nakano M, Imae T, Nakamoto T, Haga A, Nawa K, Nomura Y, Chhatkuli R, Demachi K, Takahashi W, Yamamoto K, Nakagawa K, Hashimoto M, Yoshioka Y, Oguchi M. Pseudo-CBCT image prediction of head and neck cancer patient using principal component vector fields of early treatment fractions. American Association of Physicists in Medicine. July 2019. San Antonio, USA.
4. Nakano M, Imae T, Nakamoto T, Haga A, Nawa K, Takahashi W, Nakagawa K, Hashimoto M, Yoshioka Y, Oguchi M. Pseudo-CBCT image prediction of head and neck cancer patient using principal component vector fields of early treatment fractions. 第117回日本医学物理学会学術大会. 2019. 横浜.
5. 上間達也, 村上悠, 有馬誠人, 佐藤洋輔, 吉岡稔, 佐藤智春. 強度変調回転照射の治療計画における開口形状コントローラーに関する基礎的検討. 日本放射線技術学会第47回秋季学術大会. 2019. 大阪.
6. Miyauchi H, Takahashi H, Hasegawa T, Hashimoto M. Image processing method using super-resolution technique for exposure dose reduction. 第118回日本医学物理学会学術大会. 2019. 福井.
7. 村上　悠, 上間達也, 松林史泰, 浅利崇生, 鈴木涼子, 中野正寛, 吉岡靖生, 小口正彦. VMATを用いた肺定位放射線治療におけるITV内のCT値の割り当てがGTV線量に及ぼす影響. 第32回日本高精度外部照射研究会. 2019. 東京.
8. 藤本大夢, 高津淳, 杉本聡, 笹井啓資. マーカー追跡ログを使用したInter-/Intra-Fractionによる患者呼吸波形の変化の解析. 第32回日本高精度外部照射研究会. 2019. 東京.
9. 村上　悠, 馬込大貴, 水谷拓也, 佐藤智春, 吉岡靖生, 小口正彦. 前立腺癌患者におけるRadiomics特徴量を用いた生化学的再発予測モデルの構築. 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
10. 藤本大夢, 高津淳, 原直哉, 大島理規, 鹿間直人 笹井啓資. 肺がんSBRTにおけるVMAT/3D-CRTの呼吸波形変化に対するロバスト性評価. 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
11. 津野隼人，佐々木浩二，坂本昌隆. Evaluation of uncertainty during measuring entrance surface dose in image-guided radiation therapy. 第75回日本放射線技術学会総会学術大会. 2019. 横浜.
12. Tsuno H, Sasaki K, Shimizu M, Takase N, Takahashi T, Saotome S, Miyauchi H, Sato T. Evaluation of uncertainty in electrometer calibration factor measurement using 192Ir source after electrometer separated calibration. 第118回日本医学物理学会学術大会. 2019. 福井.
13. 津野隼人, 佐々木浩二, 清水森人, 高瀬信宏, 佐藤智春. 分離校正を受けた電位計を基準とした電位計相互校正による電位計校正定数の経年変化と不確かさの評価. 第47回日本放射線技術学会秋季学術大会. 2019. 大阪.
14. Fujimoto D, Takatsu J, Hara N, Sugimoto S, Sasai K. Evaluation of the dosimetric robustness for 4DCT based internal margin against respiratory motion variations of lung cancer. 第117回日本医学物理学会学術大会. 2019. 横浜.

1. 村上　悠, 馬込大貴, 水谷拓也, 佐藤智春, 吉岡靖生, 小口正彦. 前立腺癌患者における前立腺内の石灰化が生化学的再発予測モデルに与える影響. 第33回高精度放射線外部照射部会学術大会. 2020. 福岡.
2. Murakami Y, Magome T, Matsumoto K, Sato T, Yoshioka Y, Oguchi M. Automated dose generation for intensity-modulated radiation therapy using generative adversarial networks in prostate cancer patient. 第119回日本医学物理学会学術大会. 2020. 横浜.
3. Miyauchi H, Takahashi H, Hasegawa T, Hashimoto M. Building deep learning based new super-resolution system for exposure dose reduction. 第119回日本医学物理学会学術大会. 2020. 横浜.
4. Miyauchi H, Tanaka Y, Takahashi K, Nakano M, Hasegawa T, Hashimoto M. Image processing system by super-resolution using deep learning to exposure dose reduction. 2020 Joint American Association of Physicists in Medicine (AAPM) | Canadian Organization of Medical Physicists (COMP). July 2020. Vancouver, Canada.

1. Miyauchi H, Tanaka Y, Takahashi K, Nakano M, Hasegawa T, Hashimoto M, Hashimoto T, Oguchi M, Yoshioka Y. Development of novel image processing system using super-resolution technique to reduce Cone-beam CT imaging dose in radiation therapy. ASTRO Annual Meeting 2021. October 2021. Chicago, USA.
2. Murakami Yuki, Murakami Yu, Kamima T, Hashimoto T, Oguchi M, Yoshioka Y, Dosimetric comparison between 3D conformal radiation therapy plus electron boost and simultaneous integrated boost volumetric modulated arc therapy for left-sided breast cancer patients with a potential risk of radiation-induced cardiac toxicity. 2021 ASTRO Annual Meeting. October 2021. West Chicago.
3. 村上幸, 村上悠, 上間達也, 橋本竹雄, 小口正彦, 吉岡靖生. 左乳房温存術後放射線治療における深吸気息止め照射法の最適な患者選別指標の開発. 日本放射線腫瘍学会第３４回学術大会. 2021. web
4. Ikarashi A, Murakami Y, Toshiyasu T, Yoshioka M, Kamima T, Tokumasu K, Nakano M, Hashimoto T, Oguchi M, Yoshioka Y. Prediction of late xerostomia after radiotherapy by integrating dosiomics and conventional predictive factors in patients with oropharyngeal cancer. 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting. October 2021. West Chicago.
5. 五十嵐ありさ，村上悠，利安隆史，吉岡稔，上間達也，��橋輝，徳増健二，橋本竹雄，小口正彦，吉岡靖生. 中咽頭癌患者におけるDosiomicsと従来の予測因子を用いた口腔内乾燥の予測. 日本放射線腫瘍学会第34回学術大会. 2021. web

1. 上間達也，飯野美紗恵，酒井竜平，伊藤康，榮武二，守屋駿佑，徳増健二，吉岡靖生

孤立性肺腫瘍に対するCine CTを用いた終末呼気停止中の腫瘍位置変位量の評価．日本放射線腫瘍学会第 35回学術大会．2022．広島+Web開催. [口演]

1. 松林史泰, 伊藤康 吸引式患者固定具の圧力低下がセットアップエラーに及ぼす影響．第51回日本放射線技術学会秋季学術大会．2023．名古屋+オンデマンド開催．[口演]
2. 上間達也, 守屋駿佑, 榮武二, 伊藤康，徳増健二，吉岡靖生 肺VMAT-SBRTにおける呼吸停止中の腫瘍位置変位が腫瘍投与線量に与える影響について. 日本放射線腫瘍学会第36回学術大会．2023．横浜+Web開催. [口演]
3. 宮内輝, 上間達也, 下谷内奈々, 伊藤康, 吉岡靖生 トモセラピーの線量分布を活用したKnowledge-based planningのmodel作成に関する検討. 日本放射線腫瘍学会第36回学術大会．2023．横浜+Web開催. [ポスター]

1. 佐藤佳音, 上間達也, 宮内輝, 村上幸, 伊藤康, 利安隆史, 吉岡靖生. Knowledge-based planningのmodel登録症例の治療部位が治療計画に及ぼす影響. 日本放射線腫瘍学会第37回学術大会. 2024.11. 横浜. [ポスター発表]
2. 上間達也, 明石華奈, 渡邉詩織, 松林史泰, 橘理絵, 伊藤康, 吉岡靖生. 4DCTアーチファクト画像に対する腫瘍呼吸性移動量解析ソフトウェアの実行可能性. 日本放射線腫瘍学会第37回学術大会. 2024.11. 横浜. [口演]
3. 村上幸, 上間達也, 吉岡稔，佐藤洋輔，宮内輝，佐藤佳音，伊藤康，吉岡靖生. Knowledge-based planningのmodel設定の違いが治療計画に及ぼす影響. 日本放射線腫瘍学会第37回学術大会. 2024.11. 横浜. [ポスター発表]
4. 五月女達子. VISICOILを使用したRadixactによる前立腺の追尾治療：Synchronyの使用経験について. 日本放射線腫瘍学会第37回学術大会. 2024.11. 横浜. [イブニングセミナー]

1. Murakami Y, Nakano M, Yoshida M, Hirashima H, Nakamura F, Fukunaga J, Hirose T, Yoshioka Y, Oguchi M, Hirata H. Possibility of chest wall dose reduction using volumetric-modulated arc therapy (VMAT) in radiation-induced rib fracture cases: comparison with stereotactic body radiation therapy (SBRT). J Radiat Res. 2018;59(3):327−332.
2. Kamima T, Baba H, Takahashi R, Yamashita M, Sugawara Y, Kawai D, Yamamoto T, Satou A, Tachibana H. Multi-institutional comparison of computer-based independent dose calculation for intensity modulated radiation therapy and volumetric modulated arc therapy. Phys Med. 2018;45:72-81.
3. Takahashi R, Kamima T, Itano M, Yamazaki T, Ishibashi S, Higuchi Y, Shimizu H, Yamamoto T, Yamashita M, Baba H, Sugawara Y, Sato A, Nishiyama S, Kawai D, Miyaoka S, Tachibana H. A multi-institutional study of secondary check of treatment planning using Clarkson-based dose calculation for three-dimensional radiotherapy. Phys Med. 2018;49:19-27.
4. Matsubayashi F, Takahashi R, Yoshioka M, Toshiyasu T, Sato T. Impact of respiratory motion on dose variation in radiation therapy for glottic cancer. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2018;74(11):1269-1274.
5. Jinno S, Tachibana H, Moriya S, Mizuno N, Takahashi R, Kamima T, Ishibashi S, Sato M. A multi-institutional study of independent calculation verification in inhomogeneous media using a simple and effective method of heterogeneity correction integrated with the Clarkson method. J Radiat Res. 2018;59 (4): 490-500.
6. Takei H, Isobe T, Kitamura N, Mori Y, Tomita T, Kobayashi D, Kamizawa S, Sato T, Sakurai H, Sakae T. General ion recombination effect in a liquid ionization chamber in high-dose-rate pulsed photon and electron beams. J Radiat Res. 2018;59(3):282-285.
7. Ueda Y, Fukunaga JI, Kamima T, Adachi Y, Nakamatsu K, Monzen H. Evaluation of multiple institutions' models for knowledge-based planning of volumetric modulated arc therapy (VMAT) for prostate cancer. Radiat Oncol. 2018;13(1):46.
8. Tachibana H, Uchida Y, Miyakawa R, Yamashita M, Sato A, Kito S, Maruyama D, Noda S, Kojima T, Fukuma H, Shirata R, Okamoto H, Nakamura M, Takada Y, Nagata H, Hayashi N, Takahashi R, Kawai D, Itano M. Multi-institutional comparison of secondary check of treatment planning using computer-based independent dose calculation for non-C-arm linear accelerators. Phys Med, 2018;56:58-65.

1. Murakami Y, Matsubayashi F, Magome T, Takahashi R, Arima M, Kamima T, Nakano M, Sato T, Yoshioka Y, Oguchi M. Evaluation of organ-at-risk dose reduction with jaw tracking technique in flattening filter-free beams in lung stereotactic body radiation therapy. Phys Med. 2019;61:70−76.
2. Kamima T, Ueda Y, Fukunaga J, Shimizu・Y, Tamura M, Ishikawa・ K, Monzen H. Multi-institutional evaluation of knowledge-based planning performance of volumetric modulated arc therapy (VMAT) for head and neck cancer. Phys Med. 2019;64:174-181.
3. Kamima T, Yoshioka M, Takahashi R, Sato T. Impact of DVH Outliers Registered in Knowledge-based Planning on Volumetric Modulated Arc Therapy Treatment Planning for Prostate Cancer. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2019;75(2):151-159.
4. Matsubayashi F, Takahashi R, Kamima T, Sato Y, Sato T. Influence of respiratory phase during image acquisition on prescribed dose in image guided radiation therapy using implant marker for prostate cancer. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2019;75(12):1394-1402.
5. 伊藤康. 診療放射線技師から見た「平成の医療業界」. Rad Fan. 2019;17(6):64-66.
6. 佐藤智春. 平成そして令和へ　診療放射線技師より. 臨床放射線. 2019;64(10):1291-1297.
7. Yamashita M, Takahashi R, Kokubo M, Takayama K, Tanabe H, Sueoka M, Ishii M, Tachibana H. A feasibility study of independent verification of dose calculation for Vero4DRT using a Clarkson-based algorithm. Med Dosim. 2019;44(1):20-25.

1. Murakami Y, Magome T, Matsumoto K, Sato T, Yoshioka Y, Oguchi M. Fully automated dose prediction using generative adversarial networks in prostate cancer patients. PLoS ONE. 2020;15(5): e0232697.
2. Kamima T, Murakami Y, Arima M, Sato Y, Yoshioka M, Sato T. Impact of Aperture Shape Controller on Volumetric Modulated Arc Therapy Treatment Planning for Nasopharyngeal Cancer. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2020;76(4):356-365.
3. Nakanishi R, Akiyoshi T, Toda S, Murakami Y, Taguchi S, Oba K, Nagasaki T, Matoba S, Ueno M, Fukunaga Y, Kuroyanagi H. Radiomics approach outperforms diameter criteria for predicting pathological lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in advanced low rectal cancer. Ann Surg Oncol. 2020;27:4273-4283.
4. Tamura M, Monzen H, Matsumoto K, Kubo K, Ueda Y, Kamima T, Inada M, Doi H, Nakamatsu K, Nishimura Y. Influence of cleaned-up commercial knowledge-based treatment planning on volumetric-modulated arc therapy of prostate cancer. Journal of Medical Physics. 2020;45(2): 71-77.
5. Monzen H, Tamura M, Ueda Y, Fukunaga J, Kamima T, Muraki Y, Kubo K, Nakamatsu K. Dosimetric evaluation with knowledge-based planning created at different periods in volumetric-modulated arc therapy for prostate cancer: a multi-institution study. Radiol Phys Technol. 2020;13(4):327-335.

1. Matsubayashi F, Itou Y and Hashimoto T. Invention and Evaluation of a Novel Air Leak Check System for Vacuum Type Patient Immobilization Device. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2021 77(10):1173-1179.
2. 上間達也：放射線療法~知ればケアが楽しくなる~放射線療法の基本を知る. がん看護，26巻6号, 479-482 (2021).
3. Kamima T, Ueda Y, Fukunaga JI, Tamura M, Shimizu Y, Muraki Y, Yoshioka Y, Kitamura N, Nitta Y, Otsuka M, Monzen H. Knowledge-based planning using pseudo-structures for volumetric modulated arc therapy (VMAT) of postoperative uterine cervical cancer: a multi-institutional study. Rep Pract Oncol Radiother. 2021 30;26(6):849-860.
4. Murakami Y, Soyano T, Kozuka T, Ushijima M, Koizumi Y, Miyauchi H, Kaneko M, Nakano M, Kamima T, Hashimoto T, Yoshioka Y, Oguchi M. Dose-Based Radiomic Analysis (Dosiomics) for Intensity Modulated Radiation Therapy in Patients With Prostate Cancer: Correlation Between Planned Dose Distribution and Biochemical Failure. Int J Radiat Oncol Biol Phys. 2022 1;112(1):247-259.

1. Sato Y, Shimizu M, Takeda M, Fujita Y, Kato M, Kurosawa T, Sato M. DEVELOPMENT OF ABSOLUTE MEASUREMENT SYSTEM FOR 𝑾AIR IN 60CO GAMMA RAYS. Radiat Prot Dosimetry. 2023;199(3):ncac280 262 269-276.
2. Tamura M, Ueda Y, Fukunaga JI, Kamima T, Shimizu Y, Muraki Y, Kubo K, Nakamatsu K, Hosono M, Monzen H. Impact of Knowledge-based Plan Model Improvement on Plan Complexity and Deliverability in VMAT For Prostate Cancer: A Multi-institutional Study. Anticancer Res. 2022;42(11):5305-5314.
3. Fukunaga JI, Tamura M, Ueda Y, Kamima T, Shimizu Y, Muraki Y, Nakamatsu K, Monzen H. Multi-institution model (big model) versus single-institution model of knowledge-based volumetric modulated arc therapy (VMAT) planning for prostate cancer. Sci Rep. 2022;12(1):15282.
4. Sagawa T, Ueda Y, Tsuru H, Kamima T, Ohira S, Tamura M, Miyazaki M, Monzen H, Konishi K. Dosimetric potential of knowledge-based planning model trained with HyperArc plans for brain metastases. J Appl Clin Med Phys. 2023;24(2):e13836.

1. Saotome S, Matsubayashi F, Yoshioka M, Hashimoto T, Ito Y, Oguchi M, Yoshioka Y. Effectiveness of the barcode certification system in preventing incorrect use of patient immobilization device in radiotherapy. Advance in Radiotherapy & Nuclear Medicine. 2023;1(1): 1-7
2. Kamima T, Iino M, Sakai R, Ito Y, Sakae T, Moriya S, Tokumasu K, Yoshioka Y. Evaluation of the four-dimensional motion of lung tumors during end-exhalation breath-hold conditions using volumetric cine computed tomography images. Radiother Oncol. 2023;182:109573.

1. Matsubayashi F, Takahashi T, Miyauchi H, Ito Y, Harada A, Yoshioka Y. Modeling of a tissue expander with a radiofrequency identification port in postmastectomy radiation therapy planning. J. Radiat. Res. 2024 May;65(3):360-368.
2. Matsubayashi F, Kamima T, Ito Y, Yoshioka Y. Air inflow into vacuum-type immobilization devices impacts setup errors. Radiol. Phys. Technol. 2024 Jan;17(3):697-702.
3. Ito T, Kubo K, Nakahara R, Fukunaga JI, Ueda Y, Kamima T, Shimizu Y, Hirata M, Kawamorita R, Ishii K, Nakamatsu K, Monzen H. Validating knowledge-based volumetric modulated arc therapy plans with a multi-institution model (broad model) using a complete open-loop dataset for prostate cancer. Phys Eng Sci Med. 2024 Dec 18.
4. Kamima T, Ueda Y, Fukunaga JI, Shimizu Y, Yoshioka Y, Monzen H. Enhancing Estimation Accuracy of Prostate Cancer VMAT Planning: A Knowledge-based Approach Using Multiple Collimator Angles. Anticancer Res. 2024 Dec;44(12):5303-5312.
5. 上間達也, 明石華奈, 渡邉詩織, 松林史泰, 橘理絵, 伊藤康, 吉岡靖生. 胸部動態ファントムを用いた腫瘍呼吸性移動量評価法の比較について. 日放技誌. 2024 Nov 20;80(11):1124-1134.
6. 金子真洋, 宮内春樹, 伊藤康, 吉岡靖生. Surface-guided radiotherapyの実際：ExacTrac Dynamic Surface. 臨床放射線, 69 (5): 663-669, 2024

1. 村上　悠 “がん研究振興財団 看護師・薬剤師・技師等海外研修派遣員” 2018.
2. 中野正寛 文部科学省科学研究費　研究活動スタート支援　
3. 中野正寛 文部科学省科学研究費　若手研究　
4. 上間達也 日本放射線技術学会 研究助成 2019・2020年度学術研究班 ”Artificial Intelligence技術を用いたVMAT治療計画の臨床応用に向けた多施設研究”
5. 村上　悠 “日本放射線腫瘍学会 診療放射線技師海外研修助成事業 派遣員” 2019.
6. 津野隼人 第75回日本放射線技術学会総会学術大会. JRC2019. Bronze賞. 2019. 横浜.
7. 松林史泰　日本放射線技術学会　2015年度　研究奨励賞・技術新人賞治療分野
8. 松林史泰　日本放射線技術学会　2019年度　研究奨励賞・技術奨励賞治療分野
9. 佐藤智春　日本放射線技術学会　2019年度　学術賞
10. 上間達也　日本放射線技術学会　2020年度　研究奨励賞・技術新人賞治療分野
11. 松林史泰　特許6989834「電位計の精度管理用電流発生装置、精度管理システム、及び校正方法」
12. 松林史泰　日本放射線技術学会 2022年度 学術業績賞 滝内賞
13. 松林史泰　特許7421467「吸引式患者固定具リーク検出器、検出システム、及び検出方法」
14. 吉岡靖生　日本放射線腫瘍学会2024年度 優秀教育講演賞